Symptomatic Bradycardia Due to Alectinib in a Patient with Advanced Stage of NSCLC by Ceva Wicaksono Pitoyo, Cleopas Martin Rumende, Anindita Kartika Wiraputri, Fatira Ratri Audita

Subjects: “…alectinib…”
Get full text

Chemometrically assisted optimization and validation of the HPLC method for the analysis of alectinib and its related impurity with measurement uncertainty evaluation and whiteness... by Serkan Levent, Abeer Elriş, Hazal Avcı, Saniye Özcan, Nafiz Öncü Can

Subjects: Get full text

Safety of brigatinib following alectinib-induced-pneumonitis: Case report by Blerina Resuli, Heidi Galarza, Laura Elsner, Diego Kauffmann-Guerrero, Jürgen Behr, Amanda Tufman

Subjects: “…Alectinib…”
Get full text

Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung by Naoko Imanishi, Kazue Yoneda, Akihiro Taira, Yoshinobu Ichiki, Naoko Sato, Masanori Hisaoka, Fumihiro Tanaka

Subjects: Get full text

Alectinib-Induced Hemolysis in a Case of ALK-Positive Metastatic Lung Adenocarcinoma: A Case Report with Review of Literature by Suparna Ajit Rao, Tejas Radadiya, Vidhisha Mahajan, Farah Jijina, Asha Kapadia C.

Subjects: “…alectinib…”
Get full text

The likelihood of being helped or harmed as a patient-centred tool to assess ALK-Inhibitors clinical impact and safety in ALK-addicted non-small cell lung cancer: A systematic revi... by Luca Mastrantoni, Giulia Giordano, Emanuele Vita, Guido Horn, Jacopo Russo, Armando Orlandi, Gennaro Daniele, Diana Giannarelli, Giampaolo Tortora, Emilio Bria

Subjects: Get full text

CLINICAL EFFICACY OF TARGETED THERAPY TOWARDS METASTATIC LUNG CANCER CARRYING DISTINCT TYPES OF ALK REARRANGEMENTS by N. V. Mitiushkina, I. A. Stepanov, D. O. Yurlov, E. A. Filippova, S. V. Odintsova, A. M. Lozhkina, S. V. Orlov, A. G. Iyevleva

Subjects: Get full text

Alectinib-Loaded Chitosan–Alginate Nanoparticles: A Novel Synthesis Method with In Vitro and In Vivo Evaluations by Tha’er Ata, Israa Al-Ani, Nida Karameh, Mahmood R. Atta, Wael Abu Dayyih

Subjects: “…Alectinib…”
Get full text

Lorlatinib overcomes alectinib‐induced hemolytic anemia in an ALK fusion positive non‐small‐cell lung cancer patient with severe tumor‐associated liver failure: A case report... by Kei Kunimasa, Akito Miyazaki, Motohiro Tamiya, Takako Inoue, Takahisa Kawamura, Tsunehiro Tanaka, Shun Futamura, Kiyohide Komuta, Shigenori Nagata, Keiichiro Honma, Kazuyoshi Ohkawa, Kazumi Nishino

Subjects: Get full text

Magnesium Isoglycyrrhizinate Alleviates Alectinib-Induced Hepatotoxicity by Inhibiting Mitochondrial Damage-Mediated Pyroptosis by Chen Y, Wang C, Wu Y, Zeng Y, Xie S, Weng J, Guo L, Fu J, Zhou T, Zhang X, Zhou Z

Subjects: “…alectinib…”
Get full text

Alectinib combined with VRCD and BV monoclonal antibody for the treatment of ALK-positive large B-cell lymphoma: a case report and literature review by Hongxia Wang, Junjun Bai, Bei Zhang, Zhixin Pei, Yingxin Zhao, Jingjing Gu, Zhiyu Fang, Miaomiao Liu, Xun Liang, Qinglin Song

Subjects: Get full text

Middle‐Out Physiologically Based Pharmacokinetic Modeling to Support Pediatric Dosing Recommendation for Alectinib by Tamara vanDonge, Elena Guerini, Amaury O'Jeanson, Neil Parrott, Clare Devlin, Cordula Stillhart, Nassim Djebli

Subjects: “…Alectinib…”
Get full text

Case Report: A novel ELMOD3-ALK and EML4-ALK double-fusion responses to neoadjuvant alectinib in a lung adenocarcinoma patient by Kaili Huang, Kaili Huang, Wen Li, Wen Li, Yinyin Xue, Yinyin Xue, Lei Peng, Lei Peng, Qiang Wu, Qiang Wu, Qinghua Zhou, Qinghua Zhou

Subjects: Get full text

Cost‐Effectiveness Analysis of Adjuvant Alectinib versus Platinum‐Based Chemotherapy in Resected ALK‐Positive Non‐Small‐Cell Lung Cancer in the Chinese Health Care System by Qiran Wei, Yifang Liang, Jiahui Mao, Xin Guan

Subjects: Get full text

Case Report: Ocular metastasis from ALK-rearranged pulmonary adenocarcinoma presenting as a pseudo-syndrome of anterior uveitis by Cong Zhao, Jiaqi Chen, Hongji Liu, Yan Dai

Subjects: Get full text

Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inh... by Lara Chayab, Natasha B. Leighl, Mina Tadrous, Christine M. Warren, William W. L. Wong

Subjects: Get full text

Partial response to treatment with ALK inhibitor in a patient with SQSTM1-ALK fusion positive lung adenocarcinoma by Brenda Paola Rodriguez Arroyo, Alvaro Mondragón-Cardona, Rafael Adrián Pacheco-Orozco, Andrea Tamayo, Juan Camilo Moreno, Juan Camilo Baena-Valencia

Subjects: Get full text

Successful salvage surgery followed by second ALK–TKI after alectinib failure in a patient with ALK-positive NSCLC by Hiroshi Hashimoto, Kazuyuki Komori, Koji Kameda, Shinichi Taguchi, Yuichi Ozeki

Subjects: Get full text

Integrating analytical quality by design into bioanalytical method development: an HPLC-FLD method for quantification of alectinib in biological matrix by Eun Ji Lee, Nahyun Koo, Min Ju Kim, Kyeong-Ryoon Lee, Yoon-Jee Chae

Subjects: “…Alectinib…”
Get full text

Perforation of the descending colon induced by alectinib in a patient with non-small cell lung cancer: a Case Report by Yun Li, Ping Yu, Ran Wang

Subjects: Get full text